ClinicalTrials.gg
CompletedNCT04829747Updated May 24, 2023Results posted

Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

A Phase 3 interventional study of Atogepant in Chronic Migraine, sponsored by Allergan. Completed at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
21st of 21
3 · median 468
Started
2021
with 3 others
Phase 3
15 of 21
3 open now
Registered
10th of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 21st largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 10th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

Migraine is characterized by attacks of throbbing, moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The main objective of the study is to evaluate how safe and effective the atogepant is in preventing chronic migraine in adult Chinese participants who completed study 3101-303-002. Adverse events will be monitored.

Atogepant is an investigational drug being developed to prevent chronic migraine. All participants will receive the same treatment. Approximately 120 adult participants who completed study 3101-303-002 will be enrolled at approximately 25 centers in China.

All participants will receive atogepant oral tablet once daily for 12 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Chronic Migraine

Browse trials for

Keywords

  • Chronic Migraine
  • Migraine
  • Atogepant
  • AGN-241689
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants completed the double-blind treatment period, and the safety follow-up period, if applicable, depending on the timing of study initiation, of Study 3101-303-002 without significant protocol deviations and who did not experience an adverse event (AE) that, in the investigator's opinion, may indicate an unacceptable safety risk.

Exclusion criteria

Exclusion Criteria:

  • Participants requiring any medication, diet, or nonpharmacological treatment on the list of prohibited concomitant medications or treatments, that cannot be discontinued or switched to an allowable alternative. Concomitant medications with demonstrated efficacy for the prevention of migraine is exclusionary, except that participants from lead-in study 3101-303-002 taking 1 medication with demonstrated efficacy for the prevention of migraine may participate in the current study provided that the dose was stable prior to the lead-in study and the participant is willing to continue taking that medication.
  • Participants with an (ECG) indicating abnormalities at Visit 1.
  • Participants with hypertension (sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic BP > 100 mm Hg) at Visit 1.
  • Participants with a significant risk of self-harm Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others (investigator opinion); participants who report suicidal ideation with intent, with or without a plan, since the last visit, must be excluded.
  • Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Atogepant

    Participants will receive fixed dose of Atogepant once daily for 12 weeks.

    Drug: Atogepant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity.

    Time frame: Baseline of the study 3101-303-002 to 16 weeks

  2. Number of Participants With Significant Change in Clinical Laboratory Determinations

    Number of participants with clinically significant change from baseline for any detectable clinical laboratory tests like hematology will be reported.

    Time frame: Baseline of the study 3101-303-002 to 16 weeks

  3. Number of Participants With Significant Change in Vital Sign Measurements

    Number of participants with clinically significant change from baseline for any vital signs like standing BP, sitting and standing pulse rate will be reported.

    Time frame: Baseline of the study 3101-303-002 to 16 weeks

  4. Number of Participants With Significant Change in Electrocardiogram (ECG) Parameters

    12-lead ECG will be performed.

    Time frame: Baseline of the study 3101-303-002 to 12 weeks

  5. Number of Participants With a Change in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 being wish to be dead and 5 being active suicidal ideation with specific plan and intent. Suicidal behavior is classified on a 5-item scale: 0 being no suicidal behavior and 4 being actual attempt.

    Time frame: Baseline of the study 3101-303-002 to 16 weeks

07

Results

Posted May 24, 2023

Participant flow

A total of 2 subjects were included in the modified intent-to-treat (mITT) population, defined as all subjects who received ≥1 dose of study treatment (atogepant) in this extension study and had ≥1 evaluable postbaseline 4-week period of electronic diary (eDiary) data in this extension study. A total of 3 subjects were included in the safety population, defined as all subjects who received ≥1 dose of the study treatment (atogepant) in this extension study.

Participant flow — Overall Study
MilestoneAtogepant
Started3
Completed2
Not completed1
Withdrew: Protocol violation1

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity.

Time frame:
Baseline of the study 3101-303-002 to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsAtogepant
Number of Participants With Adverse Events1
PrimaryNumber of Participants With Significant Change in Clinical Laboratory Determinations

Number of participants with clinically significant change from baseline for any detectable clinical laboratory tests like hematology will be reported.

Time frame:
Baseline of the study 3101-303-002 to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Significant Change in Clinical Laboratory Determinations
ParticipantsAtogepant
Number of Participants With Significant Change in Clinical Laboratory Determinations0
PrimaryNumber of Participants With Significant Change in Vital Sign Measurements

Number of participants with clinically significant change from baseline for any vital signs like standing BP, sitting and standing pulse rate will be reported.

Time frame:
Baseline of the study 3101-303-002 to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Significant Change in Vital Sign Measurements
ParticipantsAtogepant
Number of Participants With Significant Change in Vital Sign Measurements0
PrimaryNumber of Participants With Significant Change in Electrocardiogram (ECG) Parameters

12-lead ECG will be performed.

Time frame:
Baseline of the study 3101-303-002 to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Significant Change in Electrocardiogram (ECG) Parameters
ParticipantsAtogepant
Number of Participants With Significant Change in Electrocardiogram (ECG) Parameters0
PrimaryNumber of Participants With a Change in Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 being wish to be dead and 5 being active suicidal ideation with specific plan and intent. Suicidal behavior is classified on a 5-item scale: 0 being no suicidal behavior and 4 being actual attempt.

Time frame:
Baseline of the study 3101-303-002 to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With a Change in Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsAtogepant
Number of Participants With a Change in Columbia-Suicide Severity Rating Scale (C-SSRS)0

Adverse events

Collected over Up to 16 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atogepant0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventAtogepant
DYSMENORRHEAReproductive system and breast disorders1/3
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/3

Baseline characteristics

The safety population, consisting of all participants who received at least 1 dose of study intervention (atogepant) in this extension study.

Age, Customized
Age, Customized(Participants)Atogepant
Years of Age — 33 Years Old1
Years of Age — 41 Years Old1
Years of Age — 51 Years Old1
Sex: Female, Male
Sex: Female, Male(Participants)Atogepant
Female2
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atogepant
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atogepant
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Atogepant
China3
08

Study locations

3 sites
  • Chinese PLA General Hospital /ID# 227546
    Beijing, Beijing 100853, China
  • The Second Hospital of Shanxi Medical University /ID# 227567
    Taiyuan, Shanxi 030000, China
  • The second Affiliated hospital of Zhejiang University school of Medicine /ID# 227558
    Hangzhou, Zhejiang 310009, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jan 2022, 5 months.

Results were first posted in May 2023, 1 year 4 months after primary completion. A results delay was requested in Dec 2022.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 5 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2021
First posted
Apr 2, 2021
StartActual
Aug 2, 2021
Primary completionActual
Jan 20, 2022
CompletionActual
Jan 20, 2022
Results delay requested
Dec 21, 2022
Results first posted
May 24, 2023
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04829747
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Aug 2, 2021
Primary completion
Jan 20, 2022
Completion
Jan 20, 2022
Results posted
May 24, 2023
Last update
May 24, 2023

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion